Multi-omics analysis of gut-brain axis reveals novel microbial and neurotransmitter signatures in patients with arteriosclerotic cerebral small vessel disease

• Published in: Pharmacological research Vol. 208; p. 107385
• Main Authors: Huang, Jiayuan, Liu, Sanxin, Li, Peijie, Wei, Lei, Lin, Gan, Lin, Jiahao, Luo, Yuting, Liu, Yixin, Mao, Yudan, Ruan, Hengfang, Qin, Bing, Fan, Ping, Lu, Tingting, Cai, Wei, Yi, Haotong, Mou, Xiangyu, Lu, Zhengqi, Zhao, Wenjing, Wu, Aimin
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01-10-2024; Elsevier
• Subjects: Aged; Arteriosclerosis; Bacteria - genetics; Bacteria - metabolism; Brain-Gut Axis; Cerebral small vessel disease; Cerebral Small Vessel Diseases - metabolism; Cerebral Small Vessel Diseases - microbiology; Dysbiosis - microbiology; Female; Gastrointestinal Microbiome; Humans; Live biotherapeutic products; Male; Metabolome; Metabolomics; Microbiome; Middle Aged; Multiomics; Neurotransmitter; Neurotransmitter Agents - metabolism; Neurotransmitter; Arteriosclerosis; Cerebral small vessel disease; Microbiome; Live biotherapeutic products
• ISSN: 1043-6618; 1096-1186; 1096-1186
• DOI: 10.1016/j.phrs.2024.107385

Arteriosclerotic cerebral small vessel disease (aCSVD) is a major cause of stroke and dementia. Although its underlying pathogenesis remains poorly understood, both inflammaging and gut microbiota dysbiosis have been hypothesized to play significant roles. This study investigated the role of gut microbiota in the pathogenesis of aCSVD through a comparative analysis of the gut microbiome and metabolome between CSVD patients and healthy controls. The results showed that patients with aCSVD exhibited a marked reduction in potentially beneficial bacterial species, such as Faecalibacterium prausnitzli and Roseburia intestinalis, alongside an increase in taxa from Bacteroides and Proteobacteria. Integrated metagenomic and metabolomic analyses revealed that alterations in microbial metabolic pathways, including LPS biosynthesis and phenylalanine-tyrosine metabolism, were associated with the status of aCSVD. Our findings indicated that microbial LPS biosynthesis and phenylalanine-tyrosine metabolism potentially influenced the symptoms and progression of aCSVD via pro-inflammatory effect and modulation of systemic neurotransmitters, respectively. These results imply that gut microbiota characteristics may serve as indicators for early detection of aCSVD and as potential gut-directed therapeutic intervention target.
[Display omitted]
•Patients with aCSVD exhibited a decrease in Faecalibacterium prausnitzli and an increase in Bacteroides and Proteobacteria.•Alterations in LPS biosynthesis and phenylalanine-tyrosine metabolism were associated with aCSVD.•Microbial LPS and phenylalanine-tyrosine metabolism may influence aCSVD symptoms via inflammatory and neurotransmitter pathways.•A Support Vector Machine model effectively predicted aCSVD status using gut microbiota data.•Faecalibacterium prausnitzli and Roseburia intestinalis may be developed as live biotherapeutic products against aCSVD.